2020 Guillain-Barre Syndrome Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Guillain-Barre Syndrome pipeline report presents a comprehensive overview of the research and development of Guillain-Barre Syndrome drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Four drugs in Pre-clinical phase, one drug in Phase 1 and two drugs in Phase 2
As of February 2020, the Guillain-Barre Syndrome pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Guillain-Barre Syndrome treatment. Diverse types of targeted therapies are being explored through clinical trials including cannabinoid receptor 1 (CB1) agonist; cannabinoid receptor 2 (CB2) agonist; Complement C1 inhibitors; complement C5a inhibitor; complement C6 inhibitor; Immunoglobulin modulators; leukotriene LTB4 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Guillain-Barre Syndrome drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Guillain-Barre Syndrome pipeline drugs profiled in the report include- nomacopan, ANX005, CP 010, CV-MG01, Imlifidase, Cannabinoid receptor agonists for Central Nervous System Disorders, CK0801
As of February 2020, the Guillain-Barre Syndrome pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Guillain-Barre Syndrome treatment. Diverse types of targeted therapies are being explored through clinical trials including cannabinoid receptor 1 (CB1) agonist; cannabinoid receptor 2 (CB2) agonist; Complement C1 inhibitors; complement C5a inhibitor; complement C6 inhibitor; Immunoglobulin modulators; leukotriene LTB4 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Guillain-Barre Syndrome drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Guillain-Barre Syndrome development
- Guillain-Barre Syndrome pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Guillain-Barre Syndrome pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Guillain-Barre Syndrome pipeline candidates included
- Business overview and snapshot of all companies involved in Guillain-Barre Syndrome pipeline are included
- Latest market and pipeline developments are provided in the report
Guillain-Barre Syndrome pipeline drugs profiled in the report include- nomacopan, ANX005, CP 010, CV-MG01, Imlifidase, Cannabinoid receptor agonists for Central Nervous System Disorders, CK0801
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Guillain-Barre Syndrome Condition
2.3 Guillain-Barre Syndrome Pipeline Snapshot, 2020
2.4 Companies investing in Guillain-Barre Syndrome pipeline therapeutics
2.5 Phase wise Guillain-Barre Syndrome Pipeline Candidates
2.6 Most Researched Mechanism of Action of Guillain-Barre Syndrome Pipeline Products
2.7 Route of Administration of Guillain-Barre Syndrome Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Akari Therapeutics Plc Overview, Contacts and ASD Pipeline Drugs
3.2 Annexon Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Cellenkos Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Complement Pharma BV Overview, Contacts and ASD Pipeline Drugs
3.5 CuraVac Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Hansa Biopharma AB Overview, Contacts and ASD Pipeline Drugs
3.7 Vitality Biopharma Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 nomacopan Drug Details
4.1.1 nomacopan Current Status
4.1.2 nomacopan Drug Overview
4.1.3 nomacopan Mechanism of Action
4.1.4 nomacopan Licensing/Collaboration Companies
4.1.5 nomacopan Clinical Trials
4.2 ANX005 Drug Details
4.2.1 ANX005 Current Status
4.2.2 ANX005 Drug Overview
4.2.3 ANX005 Mechanism of Action
4.2.4 ANX005 Licensing/Collaboration Companies
4.2.5 ANX005 Clinical Trials
4.3 CP 010 Drug Details
4.3.1 CP 010 Current Status
4.3.2 CP 010 Drug Overview
4.3.3 CP 010 Mechanism of Action
4.3.4 CP 010 Licensing/Collaboration Companies
4.3.5 CP 010 Clinical Trials
4.4 CV-MG01 Drug Details
4.4.1 CV-MG01 Current Status
4.4.2 CV-MG01 Drug Overview
4.4.3 CV-MG01 Mechanism of Action
4.4.4 CV-MG01 Licensing/Collaboration Companies
4.4.5 CV-MG01 Clinical Trials
4.5 Imlifidase Drug Details
4.5.1 Imlifidase Current Status
4.5.2 Imlifidase Drug Overview
4.5.3 Imlifidase Mechanism of Action
4.5.4 Imlifidase Licensing/Collaboration Companies
4.5.5 Imlifidase Clinical Trials
4.6 Cannabinoid receptor agonists for Central Nervous System Disorders Drug Details
4.6.1 Cannabinoid receptor agonists for Central Nervous System Disorders Current Status
4.6.2 Cannabinoid receptor agonists for Central Nervous System Disorders Drug Overview
4.6.3 Cannabinoid receptor agonists for Central Nervous System Disorders Mechanism of Action
4.6.4 Cannabinoid receptor agonists for Central Nervous System Disorders Licensing/Collaboration Companies
4.6.5 Cannabinoid receptor agonists for Central Nervous System Disorders Clinical Trials
4.7 CK0801 Drug Details
4.7.1 CK0801 Current Status
4.7.2 CK0801 Drug Overview
4.7.3 CK0801 Mechanism of Action
4.7.4 CK0801 Licensing/Collaboration Companies
4.7.5 CK0801 Clinical Trials
5. LATEST GUILLAIN-BARRE SYNDROME PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Guillain-Barre Syndrome Condition
2.3 Guillain-Barre Syndrome Pipeline Snapshot, 2020
2.4 Companies investing in Guillain-Barre Syndrome pipeline therapeutics
2.5 Phase wise Guillain-Barre Syndrome Pipeline Candidates
2.6 Most Researched Mechanism of Action of Guillain-Barre Syndrome Pipeline Products
2.7 Route of Administration of Guillain-Barre Syndrome Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Akari Therapeutics Plc Overview, Contacts and ASD Pipeline Drugs
3.2 Annexon Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Cellenkos Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Complement Pharma BV Overview, Contacts and ASD Pipeline Drugs
3.5 CuraVac Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Hansa Biopharma AB Overview, Contacts and ASD Pipeline Drugs
3.7 Vitality Biopharma Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 nomacopan Drug Details
4.1.1 nomacopan Current Status
4.1.2 nomacopan Drug Overview
4.1.3 nomacopan Mechanism of Action
4.1.4 nomacopan Licensing/Collaboration Companies
4.1.5 nomacopan Clinical Trials
4.2 ANX005 Drug Details
4.2.1 ANX005 Current Status
4.2.2 ANX005 Drug Overview
4.2.3 ANX005 Mechanism of Action
4.2.4 ANX005 Licensing/Collaboration Companies
4.2.5 ANX005 Clinical Trials
4.3 CP 010 Drug Details
4.3.1 CP 010 Current Status
4.3.2 CP 010 Drug Overview
4.3.3 CP 010 Mechanism of Action
4.3.4 CP 010 Licensing/Collaboration Companies
4.3.5 CP 010 Clinical Trials
4.4 CV-MG01 Drug Details
4.4.1 CV-MG01 Current Status
4.4.2 CV-MG01 Drug Overview
4.4.3 CV-MG01 Mechanism of Action
4.4.4 CV-MG01 Licensing/Collaboration Companies
4.4.5 CV-MG01 Clinical Trials
4.5 Imlifidase Drug Details
4.5.1 Imlifidase Current Status
4.5.2 Imlifidase Drug Overview
4.5.3 Imlifidase Mechanism of Action
4.5.4 Imlifidase Licensing/Collaboration Companies
4.5.5 Imlifidase Clinical Trials
4.6 Cannabinoid receptor agonists for Central Nervous System Disorders Drug Details
4.6.1 Cannabinoid receptor agonists for Central Nervous System Disorders Current Status
4.6.2 Cannabinoid receptor agonists for Central Nervous System Disorders Drug Overview
4.6.3 Cannabinoid receptor agonists for Central Nervous System Disorders Mechanism of Action
4.6.4 Cannabinoid receptor agonists for Central Nervous System Disorders Licensing/Collaboration Companies
4.6.5 Cannabinoid receptor agonists for Central Nervous System Disorders Clinical Trials
4.7 CK0801 Drug Details
4.7.1 CK0801 Current Status
4.7.2 CK0801 Drug Overview
4.7.3 CK0801 Mechanism of Action
4.7.4 CK0801 Licensing/Collaboration Companies
4.7.5 CK0801 Clinical Trials
5. LATEST GUILLAIN-BARRE SYNDROME PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
